10-Year Experience in Performing Saturation Prostate Biopsy*

Luis Gabriel Villarraga, Jose Gustavo Ramos, José De La Hoz, Juan Guillermo Cataño Cataño


Objective: Identify the prostate cancer detection rate in patients in whom underwent
a saturation prostate biopsy as a rebiopsy from January 2005 to February 2015 at San
Ignacio Hospital. Materials and methods: In San Ignacio hospital were performed
from January 2005 to February 2015, 114 saturation biopsies. The investigators
made a univariate analysis of the variables. The association between the variable was
evaluated based on the T-test and Wilcoxon test. P < 0.05 was considered statistically
significant. Finally, a regression model was performed to predict significant variables
for prostate cancer. Results: The cancer detection rate using saturation prostate biopsy
was 16.7% of which 84% were categorized as significant. A mean of 19 cores were
obtained. There were statistically significant differences between patients with prostate
cancer and healthy patients in the number of previous biopsies, number of samples,
prostate volume and PSA density. Conclusion: Saturation prostate biopsy in our study
has a prostate cancer detection rate of 16.7% and 84% of them were significant in this
cohort of patients.

Palabras clave

biopsy; diagnosis; prostate; prostatic neoplasms

Texto completo:



Brawley OW. Prostate cancer epidemiology

in the United States. World J Urol.

;30(2):195-200. Epub 2012/04/06.

Instituto Nacional de Cancerología. Información

sobre el cancer [internet]. Instituto

Nacional de Cancerologia; 2011 [updated

; cited 2014 ene 4]. Disponible en:



Hodge KK, McNeal JE, Terris MK,

Stamey TA. Random systematic versus

directed ultrasound guided transrectal

core biopsies of the prostate. J Urol.

;142(1):71-4; discussion 4-5. Epub


Ukimura O, Coleman JA, de la Taille A,

Emberton M, Epstein JI, Freedland SJ, et

al. Contemporary role of systematic prostate

biopsies: indications, techniques, and

implications for patient care. Eur Urol.

;63(2):214-30. Epub 2012/10/02.

Naughton CK, Miller DC, Mager DE,

Ornstein DK, Catalona WJ. A prospective

randomized trial comparing 6 versus 12

prostate biopsy cores: impact on cancer

detection. J Urol. 2000;164(2):388-92.

Epub 2000/07/14.

Siu W, Dunn RL, Shah RB, Wei JT. Use

of extended pattern technique for initial

prostate biopsy. J Urol. 2005;174(2):505-

Epub 2005/07/12.

Scattoni V, Maccagnano C, Zanni G, Angiolilli

D, Raber M, Roscigno M, et al.

Is extended and saturation biopsy necessary?

Int J Urol.. 2010;17(5):432-47.

Epub 2010/04/27.

Maccagnano C, Gallina A, Roscigno M,

Raber M, Capitanio U, Sacca A, et al.

Prostate saturation biopsy following a first

negative biopsy: state of the art. Urol Int.

;89(2):126-35. Epub 2012/07/21.

Instituto Nacional de Cancerología, Sociedad

Colombiana de Urología. Guía

de práctica clínica (GPC) para la detección

temprana, diagnóstico, tratamiento

integral, seguimiento y rehabilitación de

pacientes con diagnóstico de cáncer de

próstata para el Sistema General de Seguridad

Social en Salud, Colombia [internet].

Bogotá: Ministerio de Salud y Protección

Social-Departamento Administrativo

de Ciencia Tecnología e Innovación

en Salud (Colciencias); 2013. Disponible

en: https://docs.supersalud.gov.co/




Centers for Disease Control and Prevention.

Cancer among men [internet];

[citado 2014 ene 4]. Disponible en:



Carroll PR, Parsons JK, Andriole G,

Bahnson RR, Barocas DA, Catalona WJ,

et al. Prostate cancer early detection,

version 1.2014. Featured updates to the

NCCN Guidelines. J Natl Compr Canc

Netw. 2014;12(9):1211-9; quiz 9. Epub


Mottet N, Bastian P, Bellmunt J, van den

Bergh R, Bolla M, van Casteren N, et al.

Guidelines on prostate cancer. Eur Urol.


Greene KL, Albertsen PC, Babaian RJ,

Carter HB, Gann PH, Han M, et al. Prostate

specific antigen best practice statement:

update. J Urol. 2013;189(1

Suppl):S2-S11. Epub 2012/12/19.

Djavan B, Ravery V, Zlotta A, Dobronski

P, Dobrovits M, Fakhari M, et al. Prospective

evaluation of prostate cancer detected

on biopsies 1, 2, 3 and 4: when should

we stop? J Urol. 2001;166(5):1679-83.

Epub 2001/10/05.

Roehl KA, Antenor JA, Catalona WJ. Serial

biopsy results in prostate cancer screening

study. J Urol. 2002;167(6):2435-9.

Epub 2002/05/07.

Stewart CS, Leibovich BC, Weaver AL,

Lieber MM. Prostate cancer diagnosis

using a saturation needle biopsy technique

after previous negative sextant

biopsies. J Urol. 2001;166(1):86-91; discussion

-2. Epub 2001/07/04.

Epstein JI, Walsh PC, Carmichael M,

Brendler CB. Pathologic and clinical findings

to predict tumor extent of nonpalpable

(stage T1c) prostate cancer. JAMA.

;271(5):368-74. Epub 1994/02/02.

Zaytoun OM, Moussa AS, Gao T, Fareed

K, Jones JS. Office based transrectal saturation

biopsy improves prostate cancer

detection compared to extended biopsy

in the repeat biopsy population. J Urol.

;186(3):850-4. Epub 2011/07/27.

Bjurlin MA, Meng X, Le Nobin J, Wysock

JS, Lepor H, Rosenkrantz AB, et al. Optimization

of prostate biopsy: the role

of magnetic resonance imaging targeted

biopsy in detection, localization and risk

assessment. J Urol. 2014;192(3):648-58.

Epub 2014/04/29.

Hoeks CM, Schouten MG, Bomers JG,

Hoogendoorn SP, Hulsbergen-van de Kaa

CA, Hambrock T, et al. Three-Tesla magnetic

resonance-guided prostate biopsy in

men with increased prostate-specific antigen

and repeated, negative, random, systematic,

transrectal ultrasound biopsies:

detection of clinically significant prostate

cancers. Eur Urol. 2012;62(5):902-9.

Epub 2012/02/14.

Franiel T, Stephan C, Erbersdobler A,

Dietz E, Maxeiner A, Hell N, et al. Areas

suspicious for prostate cancer: MR-guided

biopsy in patients with at least one

transrectal US-guided biopsy with a negative

finding--multiparametric MR imaging

for detection and biopsy planning.

Radiology. 2011;259(1):162-72. Epub


Sciarra A, Panebianco V, Ciccariello M,

Salciccia S, Cattarino S, Lisi D, et al. Value

of magnetic resonance spectroscopy

imaging and dynamic contrast-enhanced

imaging for detecting prostate cancer foci

in men with prior negative biopsy. Clin

Cancer Res.. 2010;16(6):1875-83. Epub


Anastasiadis AG, Lichy MP, Nagele U,

Kuczyk MA, Merseburger AS, Hennenlotter

J, et al. MRI-guided biopsy of

the prostate increases diagnostic performance

in men with elevated or increasing

PSA levels after previous negative TRUS

biopsies. Eur Urol. 2006;50(4):738-48;

discussion 48-9. Epub 2006/04/25.

DOI: http://dx.doi.org/10.11144/Javeriana.umed57-4.year

Métricas de artículo

Cargando métricas ...

Metrics powered by PLOS ALM

Copyright (c) 2017 Luis Gabriel Villarraga, Jose Gustavo Ramos, José De La Hoz, Juan Guillermo Cataño Cataño

Licencia de Creative Commons
Esta obra está registrada bajo una licencia de Creative Commons Reconocimiento 4.0 Internacional.
Creado a partir de http://revistas.javeriana.edu.co/.